ICR | Amid death risk fears, Clovis pulls Rubraca in 3rd-line ovarian cancer as PARP player plugs away at earlier setting

Amid death risk fears, Clovis pulls Rubraca in 3rd-line ovarian cancer as PARP player plugs away at earlier setting

A death risk signal has taken a toll on Clovis Oncology’s already lagging ovarian cancer drug, Rubraca. The company has taken FDA's hint, withdrawing the med in a late-line setting, but it remains undeterred in newly diagnosed patients despite an FDA warning.

The oldest independent membership-led professional body for clinical researchers across the globe.